Literature DB >> 19208832

Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.

Mary C M Weiser-Evans1, Xue-Qing Wang, Jay Amin, Vicki Van Putten, Rashmi Choudhary, Robert A Winn, Robert Scheinman, Peter Simpson, Mark W Geraci, Raphael A Nemenoff.   

Abstract

Cancer progression and metastasis involves interactions between tumor cells and the tumor microenvironment (TME). We reported that mice deficient for cytosolic phospholipase A(2) (cPLA(2)-KO) are protected against the development of lung tumors. The goal of this study was to examine the role of cPLA(2) in the TME. Mouse lung cancer cells (CMT167 and Lewis lung carcinoma cells) injected directly into lungs of syngeneic mice formed a primary tumor, and then metastasized to other lobes of the lung and to the mediastinal lymph nodes. Identical cells injected into cPLA(2)-KO mice showed a dramatic decrease in the numbers of secondary metastatic tumors. This was associated with decreased macrophage staining surrounding the tumor. Wild-type mice transplanted with cPLA(2)-KO bone marrow had a marked survival advantage after inoculation with tumor cells compared with mice receiving wild-type (WT) bone marrow. In vitro, coculturing CMT167 cells with bone marrow-derived macrophages from WT mice increased production of interleukin 6 (IL-6) by cancer cells. This increase was blocked in cocultures using cPLA(2)-KO macrophages. Correspondingly, IL-6 staining was decreased in tumors grown in cPLA(2)-KO mice. These data suggest that stromal cPLA(2) plays a critical role in tumor progression by altering tumor-macrophage interactions and cytokine production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208832      PMCID: PMC2653105          DOI: 10.1158/0008-5472.CAN-08-3766

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice.

Authors:  Xiwu Chen; Yan Su; Barbara Fingleton; Heath Acuff; Lynn M Matrisian; Roy Zent; Ambra Pozzi
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Differential regulation of gene expression during macrophage activation with a polyribonucleotide. The role of endogenously derived IFN.

Authors:  D W Riches; P M Henson; L K Remigio; J F Catterall; R C Strunk
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

3.  Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.

Authors:  Tomas J Welsh; Ruth H Green; Donna Richardson; David A Waller; Kenneth J O'Byrne; Peter Bradding
Journal:  J Clin Oncol       Date:  2005-10-11       Impact factor: 44.544

4.  Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer.

Authors:  L E Heasley; S Thaler; M Nicks; B Price; K Skorecki; R A Nemenoff
Journal:  J Biol Chem       Date:  1997-06-06       Impact factor: 5.157

5.  Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2.

Authors:  J V Bonventre; Z Huang; M R Taheri; E O'Leary; E Li; M A Moskowitz; A Sapirstein
Journal:  Nature       Date:  1997-12-11       Impact factor: 49.962

Review 6.  Prostaglandins as modulators of immunity.

Authors:  Sarah G Harris; Josue Padilla; Laura Koumas; Denise Ray; Richard P Phipps
Journal:  Trends Immunol       Date:  2002-03       Impact factor: 16.687

Review 7.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer.

Authors:  Willscott E Naugler; Michael Karin
Journal:  Trends Mol Med       Date:  2008-02-07       Impact factor: 11.951

8.  Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.

Authors:  Amy M Meyer; Lori D Dwyer-Nield; Gregory J Hurteau; Robert L Keith; Eileen O'Leary; Ming You; Joseph V Bonventre; Raphael A Nemenoff; Alvin M Malkinson
Journal:  Carcinogenesis       Date:  2004-03-19       Impact factor: 4.944

Review 9.  Multifaceted roles of cyclooxygenase-2 in lung cancer.

Authors:  Karen Riedl; Kostyantyn Krysan; Mehis Põld; Harnisha Dalwadi; Nathalie Heuze-Vourc'h; Mariam Dohadwala; Ming Liu; Xiaoyan Cui; Robert Figlin; Jenny T Mao; Robert Strieter; Sherven Sharma; Steven M Dubinett
Journal:  Drug Resist Updat       Date:  2004-06       Impact factor: 18.500

10.  Heterogeneity in a spontaneous mouse lung carcinoma: selection and characterisation of stable metastatic variants.

Authors:  M G Layton; L M Franks
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

View more
  24 in total

Review 1.  Cytosolic phospholipase A₂: physiological function and role in disease.

Authors:  Christina C Leslie
Journal:  J Lipid Res       Date:  2015-04-02       Impact factor: 5.922

2.  PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages.

Authors:  Sreedevi Avasarala; Pei-Ying Wu; Samia Q Khan; Su Yanlin; Michelle Van Scoyk; Jianqiang Bao; Alessandra Di Lorenzo; Odile David; Mark T Bedford; Vineet Gupta; Robert A Winn; Rama Kamesh Bikkavilli
Journal:  Mol Cancer Res       Date:  2019-10-16       Impact factor: 5.852

3.  The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.

Authors:  Howard Y Li; Maria McSharry; Bonnie Bullock; Teresa T Nguyen; Jeff Kwak; Joanna M Poczobutt; Trisha R Sippel; Lynn E Heasley; Mary C Weiser-Evans; Eric T Clambey; Raphael A Nemenoff
Journal:  Cancer Immunol Res       Date:  2017-08-17       Impact factor: 11.151

4.  The RNA-binding protein HuR stabilizes cytosolic phospholipase A2α mRNA under interleukin-1β treatment in non-small cell lung cancer A549 Cells.

Authors:  Wan-Lin Liao; Wei-Chiao Wang; Wen-Chang Chang; Joseph T Tseng
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

5.  Bone marrow-derived cPLA2α contributes to renal fibrosis progression.

Authors:  John R Montford; Allison M B Lehman; Colin D Bauer; Jelena Klawitter; Jost Klawitter; Joanna M Poczobutt; Micah Scobey; Mary Weiser-Evans; Raphael A Nemenoff; Seth B Furgeson
Journal:  J Lipid Res       Date:  2017-12-11       Impact factor: 5.922

6.  Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.

Authors:  Howard Y Li; Maria McSharry; Deandra Walker; Amber Johnson; Jeff Kwak; Bonnie Bullock; Alexander Neuwelt; Joanna M Poczobutt; Trisha R Sippel; Robert L Keith; Mary C M Weiser-Evans; Eric Clambey; Raphael A Nemenoff
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

7.  Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.

Authors:  Jeff W Kwak; Jennifer Laskowski; Howard Y Li; Maria V McSharry; Trisha R Sippel; Bonnie L Bullock; Amber M Johnson; Joanna M Poczobutt; Alexander J Neuwelt; Stephen P Malkoski; Mary C Weiser-Evans; John D Lambris; Eric T Clambey; Joshua M Thurman; Raphael A Nemenoff
Journal:  Cancer Res       Date:  2017-11-08       Impact factor: 12.701

Review 8.  Mechanisms linking obesity and cancer.

Authors:  Sharon M Louie; Lindsay S Roberts; Daniel K Nomura
Journal:  Biochim Biophys Acta       Date:  2013-03-05

9.  Low molecular weight hyaluronan activates cytosolic phospholipase A2α and eicosanoid production in monocytes and macrophages.

Authors:  Milena Sokolowska; Li-Yuan Chen; Michael Eberlein; Asuncion Martinez-Anton; Yueqin Liu; Sara Alsaaty; Hai-Yan Qi; Carolea Logun; Maureen Horton; James H Shelhamer
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

Review 10.  Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.

Authors:  Andrei Laszlo; Dinesh Thotala; Dennis E Hallahan
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.